CVRdatabase
Menu

Synact Pharma ApS

Private limited companyCVR 34459975HolteActive

Synact Pharma ApS is a private limited company, based in Holte, active in manufacture of pharmaceutical preparations, founded in 2012. The company made a loss in both 2024 and 2025, most recently DKK 59.8m. Equity fell to DKK 20.3m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 53.2m−102.5% vs. 2024
Net profit−DKK 59.8m−96.3% vs. 2024
EquityDKK 20.3m−19.2% vs. 2024
Employees7latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 30.5m to DKK 59.8m (2024 → 2025).
  • Equity fell 19% (2024 → 2025), to DKK 20.3m.

Employees

  • 1 more employees than a year earlier: 7 (08/2026) against 6 (08/2025).

Management and owners, last 24 months

  • New in management: Ann Kristin Brøgger Led (director, 10/03/2026).
  • Stepped down: Björn Uno Bernhard Westberg (director, 10/03/2026).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 80m−DKK 60m−DKK 40m−DKK 20mDKK 0DKK 20mDKK 40m202020212022202320242025
EquityNet profit
Financial figures for Synact Pharma ApS
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit−16,676−43,430−46,951−63,448−26,275−53,195−102.5%
Operating profit (EBIT)−16,963−46,550−55,222−70,869−36,035−65,223−81%
Profit before tax−17,381−46,658−55,280−70,909−35,977−65,313−81.5%
Net profit−14,002−41,157−49,780−65,409−30,477−59,813−96.3%
Total assets12,69113,54437,94726,78537,79232,004−15.3%
Equity11,3576,64933,99515,58625,10920,296−19.2%
Liabilities1,3346,8953,8527,17211,32710,476−7.5%
Cash and cash equivalents6,4522,91913,15012,1398,83311,660+32%
Average number of employees–23340−100%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 70m−DKK 60m−DKK 50m−DKK 40m−DKK 30m−DKK 20m−DKK 10mDKK 0202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Synact Pharma ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202502/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202427/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202320/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202230/05/2023The companyPDFXBRL
202101/01/2021 – 31/12/202124/05/2022The companyPDFXBRL
202001/01/2020 – 31/12/202031/05/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0123456709/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 53.2mNo. 53 of 57
Better than 7% of the companies in the industry
EquityDKK 20.3mNo. 24 of 59
Better than 60% of the companies in the industry
Number of employees7No. 52 of 59
Better than 12% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,729of 69,742
Better than 0%
No. 5,734of 69,964
Better than 92%
Same industry and fewer than 20 employees37 companies in the comparison
No. 34of 36
Better than 6%
No. 8of 37
Better than 81%
Companies that are between 5 and 14 years old33,679 companies in the comparison
No. 33,565of 33,579
Better than 0%
No. 2,288of 33,678
Better than 93%
All companies of type ApS66,508 companies in the comparison
No. 66,367of 66,379
Better than 0%
No. 4,196of 66,505
Better than 94%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Synact Pharma ApS−DKK 53.2m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Synact Pharma ApS−DKK 59.8m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Synact Pharma ApSDKK 20.3m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Synact Pharma ApS7
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • SynAct Pharma AB100%
Synact Pharma ApS

Management

3 active registrations

Executive management

Executive management at Synact Pharma ApS
NameRoleAppointed
Thomas BoesenDirector25/05/2023
Jeppe Øvli ØvlesenCEO20/03/2024
Ann Kristin Brøgger LedDirector10/03/2026
Auditor
KPMG P/S
Founders
Nordic Biotech Holding ApS
Former management (11)
Former management at Synact Pharma ApS
NameRoleAppointedResigned
Sigbjørn Georg Nielsen KjærgårdCEO14/03/201217/08/2015
Sigbjørn Georg Nielsen KjærgårdBoard member14/08/201210/03/2016
Jørn Frederik FalchBoard member16/12/201309/02/2015
Uli Alf HacksellChair of the board16/12/201316/02/2015
Otto Bjerg HausgaardChair of the board16/02/201510/03/2016
Jeppe Øvli ØvlesenCEO17/08/201525/05/2023
Thomas Engelbrecht Nordkild JonassenBoard member17/08/201510/03/2016
Henrik StageDirector10/03/201618/01/2022
Patrik RenbladDirector18/01/202215/06/2023
Torbjørn BjerkeCEO25/05/202320/03/2024
Björn Uno Bernhard WestbergDirector15/06/202310/03/2026

Signing rule: Selskabet tegnes af to direktører i forening.

Address and production units

1 active production units

Dronninggårds Alle 136
2840 Holte

Rudersdal Municipality · Postcode 2840

Other companies at the address (2)

Production units
Production unitAddressEmployeesP number
SYNACT PHARMA ApSDronninggårds Alle 136, 2840 Holte71017548502

Purpose

Selskabets formål er at udvikle lægemidler og dermed relateret virksomhed samt enhver aktivitet, der efter direktionens skøn står i forbindelse hermed.

The purpose is quoted from the register in Danish.

Changes year by year

57 registered events
20263 changesaccounts 1 · management 2
  • Annual report for 2025 published
  • Ann Kristin Brøgger Led appointed director
  • Björn Uno Bernhard Westberg stepped down as director
20251 changeaccounts 1
  • Annual report for 2024 published
20243 changesaccounts 1 · management 2
  • Annual report for 2023 published
  • Jeppe Øvli Øvlesen appointed ceo
  • Torbjørn Bjerke stepped down as ceo
20236 changesmanagement 5 · accounts 1
  • Björn Uno Bernhard Westberg appointed director
  • Patrik Renblad stepped down as director
  • Annual report for 2022 published
  • Thomas Boesen appointed director
  • Torbjørn Bjerke appointed ceo
  • Jeppe Øvli Øvlesen stepped down as ceo
20223 changesaccounts 1 · management 2
  • Annual report for 2021 published
  • Patrik Renblad appointed director
  • Henrik Stage stepped down as director
20211 changeaccounts 1
  • Annual report for 2020 published
201622 changescapital 2 · address 2 · ownership 14 · management 4
  • Share capital changed from 60,000 DKK to 1,000,000 DKK
  • Moved to Dronninggårds Alle 136, 2840 Holte
  • SynAct Pharma AB registered as owner (100%)
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • QUANTASS ApS is no longer registered as owner
  • Next Stage Ventures ApS is no longer registered as owner
  • GL Capital AB is no longer registered as owner
  • NORDIC BIOTECH HOLDING ApS is no longer registered as owner
  • Moved to Turbinevej 1, 3150 Hellebæk
  • Share capital changed from 476,947 DKK to 60,000 DKK
  • Henrik Stage appointed director
  • Thomas Engelbrecht Nordkild Jonassen stepped down as board member
  • Otto Bjerg Hausgaard stepped down as chair of the board
  • Sigbjørn Georg Nielsen Kjærgård stepped down as board member
  • TJ BIOTECH HOLDING ApS registered as owner (33.33%)
  • QUANTASS ApS registered as owner (25%)
  • Next Stage Ventures ApS registered as owner (5%)
  • GL Capital AB registered as owner (10%)
  • NORDIC BIOTECH HOLDING ApS registered as owner (5%)
  • TJ BIOTECH HOLDING ApS is no longer registered as owner
  • NORDIC BIOTECH HOLDING ApS is no longer registered as owner
  • Forsknings-, Uddannelses- og Digitaliseringsministeriet is no longer registered as owner
20157 changesmanagement 6 · address 1
  • Jeppe Øvli Øvlesen appointed ceo
  • Thomas Engelbrecht Nordkild Jonassen appointed board member
  • Sigbjørn Georg Nielsen Kjærgård stepped down as ceo
  • Moved to Åbogade 15, 8200 Aarhus N
  • Otto Bjerg Hausgaard appointed chair of the board
  • Uli Alf Hacksell stepped down as chair of the board
  • Jørn Frederik Falch stepped down as board member
20132 changesmanagement 2
  • Uli Alf Hacksell appointed chair of the board
  • Jørn Frederik Falch appointed board member
20129 changescapital 1 · management 2 · ownership 3 · address 1 · name 1 · founded 1
  • Share capital changed from 80,000 DKK to 476,947 DKK
  • Sigbjørn Georg Nielsen Kjærgård appointed board member
  • TJ BIOTECH HOLDING ApS registered as owner (0%)
  • NORDIC BIOTECH HOLDING ApS registered as owner (33.33%)
  • Forsknings-, Uddannelses- og Digitaliseringsministeriet registered as owner (25%)
  • Moved to Brendstrupgårdsvej 102, 8200 Aarhus N
  • Name changed from SYNACTION PHARMA ApS to SYNACT PHARMA ApS
  • Registered as SYNACTION PHARMA ApS
  • Sigbjørn Georg Nielsen Kjærgård appointed ceo

Related companies

Same industry in Rudersdal

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction